Rhumbline Advisers Has $1.15 Million Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Rhumbline Advisers increased its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 11.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,650 shares of the company’s stock after acquiring an additional 4,497 shares during the quarter. Rhumbline Advisers owned approximately 0.07% of Janux Therapeutics worth $1,152,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Legal & General Group Plc raised its holdings in shares of Janux Therapeutics by 45.3% during the fourth quarter. Legal & General Group Plc now owns 34,540 shares of the company’s stock valued at $1,849,000 after purchasing an additional 10,776 shares during the period. Millennium Management LLC acquired a new position in Janux Therapeutics during the 4th quarter worth approximately $6,216,000. Swiss National Bank boosted its holdings in Janux Therapeutics by 94.3% in the fourth quarter. Swiss National Bank now owns 79,100 shares of the company’s stock worth $4,235,000 after acquiring an additional 38,400 shares in the last quarter. California State Teachers Retirement System grew its stake in Janux Therapeutics by 82.2% in the fourth quarter. California State Teachers Retirement System now owns 36,735 shares of the company’s stock valued at $1,967,000 after acquiring an additional 16,575 shares during the period. Finally, Proficio Capital Partners LLC bought a new stake in shares of Janux Therapeutics during the fourth quarter valued at approximately $1,353,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on JANX. Scotiabank cut their target price on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 28th. Wedbush reiterated an “outperform” rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $95.25.

Janux Therapeutics Price Performance

NASDAQ JANX opened at $22.72 on Friday. The company has a fifty day moving average price of $26.77 and a 200-day moving average price of $36.44. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -16.71 and a beta of 2.96. Janux Therapeutics, Inc. has a 1 year low of $22.48 and a 1 year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 9.29%. On average, research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Insider Transactions at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the firm’s stock in a transaction on Monday, April 21st. The stock was sold at an average price of $30.00, for a total transaction of $100,020.00. Following the completion of the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at $2,464,170. This trade represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 8.10% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.